Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus SBRT in advanced oligometastatic NSCLC
NCT04306926Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04306926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306926.